CPHI Podcast Series: AI transforming pharma manufacturing
This episode explores how AI is revolutionising the pharmaceutical industry, from "smart factories" to seamless supply chain integration, and discuss the transformative advancements shaping the next decade.
In the latest episode of the podcast, host Lucy Chard sits down with David Staunton of Cognizant to delve into the groundbreaking impact of artificial intelligence (AI) on the pharmaceutical industry.
Together, they explore how AI is revolutionising every stage of the pharma value chain, from manufacturing to packaging and distribution.
The discussion highlights the emergence of "smart factories", facilities that leverage AI to optimise production processes, enhance efficiency, and ensure precision. David explains what makes a factory truly "smart" and how specialised facilities for drug substances, drug products, and packaging are integrating AI in unique ways to meet their distinct technological demands.
Listeners will gain insights into how AI is accelerating the launch of new pharmaceutical products, streamlining manufacturing workflows, and ensuring seamless connectivity across the supply chain. The episode also looks ahead to the next decade, forecasting the transformative changes AI will bring to the industry, including innovations that promise to reshape the way medicines are developed, produced, and delivered.
David is the Life Science Manufacturing Leader of Transformation at Cognizant and drives business outcome transformation with our Tier 1 Clients. David has over 25 years’ experience in delivering Digital, MES, Data and Automation projects and services for Pharma and Biotech Companies.
In consistent dialogue with CIOs, Global VPs of Engineering, Quality VPs and Site Heads of GMP Manufacturing and Lab facilities, David leads the delivery of Transformation Services for Industry 4.0. David is an internationally recognised speaker on Industry 4.0 and lectures on a variety UCD Master’s Programmes.
An innovator in the Life Science Industry, David recognises the transformative potential of AI, heralding it as a game changer in areas from drug discovery to operational efficiency and ESG. Transforming the economics making medicine David is equipped with a practical and contemporary approach from engagements with Tier 1 Pharma companies, that are steering the sector towards a future where accelerated launch, predictive analytics, and unparalleled efficiency are the norm.
This episode is a must-listen for anyone interested in the intersection of technology and healthcare, offering a compelling glimpse into the future of pharma.
Related News
-
News AI-powered therapy offers hope for rare familial polyposis
Recursion Pharmaceuticals has announced promising results from its ongoing early- to mid-stage trial evaluating its AI-powered treatment, REC-4881, for familial adenomatous polyposis (FAP).
-
News AstraZeneca invests in AI-led research agreement with China's CSPC, up to US$5.3 billion
Anglo-Swedish pharmaceutical giant AstraZeneca announced they have signed a deal with China’s CSPC Pharmaceutical Group worth up to US$5.3 billion to drive AI-led research development of therapies for chronic conditions.
-
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News How GLP-1 agonists are reshaping drug delivery innovations
GLP-1 agonist drug products like Ozempic, Wegovy, and Mounjaro have taken the healthcare industry by storm in recent years. Originally conceived as treatment for Type 2 diabetes, the weight-loss effects of these products have taken on unprecedented int... -
News 2025 Pharma Trends Outlook: Collaborative Pharma – A New Era of Supply Chains
A new year, a new Pharma Trends Outlook report! The 2025 Pharma Trends Outlook report examines key changes expected in the pharmaceutical industry for the coming year, particularly in regards to the supply chain.
-
News AI-driven drug discovery model sets new accuracy prediction benchmark
Iambic Therapeutics, an Nvidia-backed biotech based in London, have stated that their AI drug discovery model named ‘Enchant’ demonstrates the potential to reduce the time and cost associated with new drug development.
-
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma.
-
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain.